The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer
Table 2
Patient population description.
Population description
Value2
Sex
950
Male
600 (63.2%)
Female
350 (36.8%)
Age
950
64.0 (42.0–84.0)
<50
153 (16.1%)
50–65
356 (37.5%)
65–80
327 (34.4%)
>80
114 (12.0%)
Histology
950
Adenocarcinoma
226 (23.8%)
Squamous cell carcinoma
261 (27.5%)
Small cell carcinoma
175 (18.4%)
Large cell carcinoma
61 (6.4%)
Small cell carcinoma not otherwise specified
113 (11.9%)
Other
80 (8.4%)
Not determined
34 (3.6%)
Clinical stage
823
I
80 (9.7%)
II
76 (9.2%)
III
274 (33.3%)
IV
393 (41.4%)
Initial treatment
950
Chemotherapy
605 (63.7%)
Radiotherapy
45 (4.7%)
Surgery
149 (15.7%)
Biological therapy
25 (2.6%)
Symptomatic treatment
126 (13.3%)
Smoking
907
799 (88.1%)
COPD
950
363 (38.2%)
Diabetes mellitus
950
184 (19.4%)
Cerebrovascular disease
950
91 (9.6%)
Hypertension
950
376 (39.6%)
Heart failure
950
73 (7.7%)
Atrial fibrillation
950
61 (6.4%)
Obesity
950
78 (8.2%)
Platelets at the time of diagnosis
950
286.5 (107.0–488.0)
WBC
950
7.0 (1.9–12.5)
Hemoglobin
950
122.0 (93.0–154.0)
PT
926
1.0 (0.7–1.7)
aPTT
925
34.5 (24.6–44.4)
Fibrinogen
874
3.1 (1.8–5.7)
D-dimers
811
0.4 (0.2–0.6)
Thromboembolic event 6 months after treatment initiation
950
91 (9.6%)
Severity of thromboembolic event
91
Nonserious
11 (12.1%)
Serious
80 (87.9%)
Available . Categorical variables are described by absolute and relative frequencies; continuous variables are described by median and 5%–95% percentiles.
